Latest News and Press Releases

  Geneva, Switzerland and Boston, MA – Tuesday 14, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of...

  Geneva, Switzerland and Boston, MA – April 6, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s...

Geneva, Switzerland and Boston, MA – March 27, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s...

  Patient safety remains the top priority PRIMROSE 1 and PRIMROSE 2 trial results expected to be announced in Q2:20, as planned PROLONG trial results expected to be announced in 2H:20, as...

  Geneva, Switzerland and Boston, MA – March 5, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s...

  Primary endpoint achieved in 94% of women in linzagolix Phase 3 PRIMROSE 2 trial in uterine fibroids Linzagolix Phase 3 PRIMROSE 1 six-month primary endpoint results and PRIMROSE 2 twelve-month...

  Geneva, Switzerland and Boston, MA – February 27, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s...

Geneva, Switzerland and Boston, MA – February 18, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s...

Geneva, Switzerland and Boston, MA – February 18, 2019 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s...

  Phase 3 linzagolix trials expected to generate additional data in uterine fibroids in Q2:20 with first linzagolix regulatory filing planned for late 2020Enrollment of linzagolix US and EU Phase 3...